Ascenta Therapeutics Inc. and The Leukemia & Lymphoma Society Announce Agreement to Develop AT-406 for Leukemia

06 Dec 2010

·www.biospace.com

Small molecular drug

MALVERN, Pa. & WHITE PLAINS, N.Y.--(BUSINESS WIRE)--Ascenta Therapeutics, Inc. and The Leukemia & Lymphoma Society (LLS) today entered into an agreement whereby the LLS will support clinical development of Ascenta’s oral small molecule inhibitor of IAPs (inhibitor of apoptosis proteins), AT-406, for patients with acute myeloid leukemia (AML).

Organizations

Ascenta Therapeutics, Inc.

Indications

LeukemiaLymphomaAdult Acute Myeloblastic Leukemia

Targets

IAP

Drugs

Xevinapant

Chat with Hiro

Hot reports

GPRC5D Target Patent Research Report

Patsnap Synapse

Global Drug R&D Express (July 2024)

PatSnap Synapse

siRNA Drug Amvuttra Patent Research and Practical Operation Guide

Patsnap Synapse

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.